Kopran Limited has announced a board meeting scheduled for January 22, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued a formal notice to stock exchanges regarding this important corporate development.

Board Meeting Details

The meeting specifics have been structured as follows:

Regulatory Compliance

The board meeting announcement has been made in accordance with Regulation 29(1) of the SEBI (LODR) Regulations, 2015. This regulatory framework mandates listed companies to provide advance notice of board meetings where material decisions, including financial results approval, are scheduled for consideration.

Trading Window Restrictions

Kopran Limited has implemented trading window restrictions as part of its commitment to fair disclosure practices. The company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information governs these restrictions.

The trading window closure prevents insiders from dealing in company securities during the period when unpublished price-sensitive information is available. This measure ensures compliance with insider trading regulations and maintains market integrity.

Corporate Communication

The formal notice was signed by Sunil Sodhani, Company Secretary and Compliance Officer, with membership number FCS 3897. The communication was digitally signed on January 13, 2026, and has been disseminated to both BSE Limited and the National Stock Exchange of India Limited for public disclosure.

Kopran Limited, incorporated in 1958 with CIN L24230MH1958PLC011078, operates from its registered office at Parijat House, Worli, Mumbai, with manufacturing facilities in Raigad district. The company's upcoming board meeting represents a routine quarterly disclosure requirement that provides stakeholders with transparency regarding financial performance.

Kopran Limited has received a credit rating reaffirmation from CRISIL for its bank loan facilities and those of its subsidiary company, with the ratings remaining valid till March 31, 2026. The rating agency has placed both entities on rating watch with developing implications while maintaining their existing credit ratings.

Credit Rating Details for Kopran Limited

CRISIL has reaffirmed the credit ratings for Kopran Limited's bank loan facilities totaling ₹69.31 crores. The rating structure includes both long-term and short-term components:

Both ratings have been placed on rating watch with developing implications, indicating that CRISIL is monitoring certain developments that could potentially impact the company's creditworthiness.

Subsidiary Company Rating Reaffirmation

Kopran Research Laboratories Limited, the subsidiary company, has also received rating reaffirmation for its significantly larger bank loan facilities:

The subsidiary's facilities, valued at ₹124.75 crores, are nearly double the parent company's facilities and carry identical rating designations with the same watch developing status.

Regulatory Compliance and Disclosure

The rating update has been communicated to both BSE Limited and the National Stock Exchange of India Limited as part of regulatory compliance requirements. The company has confirmed that this information will be made available on its official website at www.kopran.com , in accordance with Regulation 30(8) of the SEBI Regulations.

The communication was signed by Sunil Sodhani, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols are followed in the disclosure process.